At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Revusirandrug
Likely dose
Revusiran 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate the Efficacy and Safety of Revusiran in Patients With Transthyretin-mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post-Orthotopic Liver Transplant
In Brief
A Phase 2 clinical trial evaluating Revusiran for Transthyretin (TTR)-Mediated Amyloidosis and 3 related conditions. Completed, enrolled 12 participants across 6 sites in 6 countries.
Detailed Summary
The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis (ATTR), whose disease has continued to worsen after liver transplantation. Dosing has been discontinued; patients are being followed-up for safety.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransthyretin (TTR)-Mediated Amyloidosis, Familial Amyloidotic Polyneuropathy (FAP), ATTR Amyloidosis, Familial Amyloid Neuropathies
CountriesFrance, Germany, Portugal, Spain, Sweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedNov 2015
Primary CompletionFeb 2017
TodayJul 2026
First PostedNov 4, 2015
Enrollment StartOct 1, 2015
Primary CompletionFeb 6, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.7 years ago
Interventions
Revusirandrug
500mg Revusiran by subcutaneous (sc) injection